Calydon Capital Has $830,000 Stake in Astrazeneca Plc $AZN

Calydon Capital reduced its position in Astrazeneca Plc (NYSE:AZN) by 65.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,822 shares of the company’s stock after selling 20,282 shares during the quarter. Calydon Capital’s holdings in Astrazeneca were worth $830,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Bank of Montreal Can increased its holdings in Astrazeneca by 344.6% in the 3rd quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock valued at $266,841,000 after buying an additional 2,695,793 shares during the period. Fayez Sarofim & Co lifted its holdings in shares of Astrazeneca by 173.4% during the 2nd quarter. Fayez Sarofim & Co now owns 3,745,902 shares of the company’s stock worth $261,764,000 after acquiring an additional 2,376,032 shares during the period. Raymond James Financial Inc. lifted its holdings in shares of Astrazeneca by 64.8% during the 2nd quarter. Raymond James Financial Inc. now owns 3,783,251 shares of the company’s stock worth $264,373,000 after acquiring an additional 1,487,662 shares during the period. Bank of America Corp DE boosted its position in shares of Astrazeneca by 4.7% during the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock valued at $2,503,614,000 after acquiring an additional 1,461,786 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board acquired a new stake in shares of Astrazeneca during the 2nd quarter valued at about $96,936,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Astrazeneca Price Performance

Shares of AZN stock opened at $190.20 on Friday. Astrazeneca Plc has a 12-month low of $122.48 and a 12-month high of $212.71. The stock has a market cap of $294.98 billion, a P/E ratio of 29.04, a PEG ratio of 1.43 and a beta of 0.32. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51.

Astrazeneca Dividend Announcement

The company also recently disclosed a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be issued a dividend of $1.595 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca’s dividend payout ratio (DPR) is presently 66.26%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research report on Friday, February 6th. Citigroup initiated coverage on Astrazeneca in a report on Tuesday, January 27th. They set a “buy” rating on the stock. HSBC reiterated a “buy” rating and issued a $108.00 price objective on shares of Astrazeneca in a research note on Wednesday, December 10th. Guggenheim restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, December 3rd. Finally, Wall Street Zen lowered Astrazeneca from a “buy” rating to a “hold” rating in a research note on Thursday. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $95.75.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.